The company has now recruited clinical trial sites across Europe as part of the global REMAP-CAP study.

Biotech company Dimerix (ASX:DXB) has continued its recent run of positive news flow, with a market update on its collaboration with the global REMAP-CAP study into treatments for COVID-19.

The company has now completed a study confirming that nasogastric delivery (via feeding tube) is a safe and acceptable delivery method for a DMX-200 formulation, and can be provided to patients in intensive care who are unable to swallow a capsule.

The result means DXB’s proprietary DMX-200 drug treatment is now ready and available for recruitment across Europe, where COVID-19 cases continue to climb.

While vaccine rollouts are underway, the introduction of other advanced COVID-19 treatments remains crucial to overall health outcomes, Dimerix said.

In that context, the availability of DMX-200 could be a key factor as the global REMAP-CAP study network ramps up testing.

 

Global study

Endorsed by the World Health Organisation, the REMAP-CAP study is currently investigating more than 20 active treatments for COVID-19.

The study is recruiting around 100 patients a week across Europe, where it’s being funded directly by the European Union, and has initiated a master protocol across more than 290 clinical sites in eight global regions

The study’s lead European investigator, Dr Lennie Derde (MD PhD) said the availability of DMX-200 in the development of COVID-19 treatments was a “very exciting” development.

“We use innovative trial design to test a novel drug for the treatment of patients with COVID-19. Our collaboration with Dimerix gives us the best of both worlds,” Derde said.

In the context of the broader REMAP-CAP study, DMX-200 is a new investigational drug used in specific intervention studies aimed at the renin-angiotensin system, to help ease symptoms of patients suffering from COVID-19.

The protocol for the specific domain, called the “ACE2-RAS domain”, was published last year and presented to European regulators.

Through the University Medical Center Utrecht (UMCU) in Utrecht, Netherlands, Dimerix has now contracted with multiple REMAP-CAP clinical sites across Europe (including the UK).

Along with advancements in the use of DMX-200 as part of the REMAP-CAP study, Dimerix continues to build towards key Phase 3 trials for DMX-200 in the treatment of Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease.

With a busy year ahead, Dimerix CEO Nina Webster said the ongoing REMAP-CAP study was an exciting pathway to test the validity of DMX-200 in multiple use-cases, including COVID-19 treatments.

“We are delighted to be working with such a high calibre team towards helping reduce the burden of COVID-19 in patients globally, as well as address respiratory complications commonly associated with pneumonia more broadly,” Webster said.

This article was developed in collaboration with Dimerix, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

 

Read MoreHealth

Featured Companies

You might be interested in